33,543 Pfizer Inc. $PFE Shares Sold by Illinois Municipal Retirement Fund

by · The Markets Daily

Illinois Municipal Retirement Fund decreased its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 4.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 750,341 shares of the biopharmaceutical company’s stock after selling 33,543 shares during the period. Illinois Municipal Retirement Fund’s holdings in Pfizer were worth $21,400,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of PFE. BlackRock Inc. raised its position in shares of Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares in the last quarter. State Street Corp boosted its position in Pfizer by 1.8% during the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Pfizer by 11.1% during the first quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company’s stock valued at $1,512,948,000 after purchasing an additional 5,364,929 shares in the last quarter. Bank of America Corp DE purchased a new position in Pfizer in the second quarter valued at about $1,049,602,000. Finally, Dimensional Fund Advisors LP grew its stake in Pfizer by 0.8% in the first quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock valued at $1,022,606,000 after purchasing an additional 293,029 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

  • Positive Sentiment: Pfizer reported positive Phase 3 MagnetisMM-32 results for ELREXFIO in patients with relapsed or refractory multiple myeloma, supporting the drug’s potential use after prior treatments. The company also partnered with Edison Scientific to apply AI tools across its research pipeline, which could support drug discovery. Pfizer Phase 3 and AI research article
  • Positive Sentiment: Pfizer raised its 2026 revenue outlook by $1.5 billion at the midpoint, to $62 billion–$64 billion. The report attributes the improved outlook to business momentum and puts renewed attention on the company’s growth prospects. Pfizer higher 2026 outlook article
  • Positive Sentiment: Commentary points to growth from recently launched and acquired products, while Pfizer’s Metsera acquisition gives it potential exposure to the GLP-1 market. However, its obesity treatment may not launch until 2028, making this a longer-term opportunity rather than a near-term revenue driver. Pfizer product growth article Pfizer GLP-1 opportunity article
  • Neutral Sentiment: Cecile Guegan has become Pfizer’s permanent CFO, the company’s first woman in the role. The appointment comes as Pfizer manages major pipeline investments, including obesity-drug development; the report does not indicate an immediate financial impact. Pfizer CFO appointment article
  • Neutral Sentiment: Arbutus Biopharma and Genevant expanded patent lawsuits against Pfizer and BioNTech in Japan and Canada over lipid nanoparticle technology used in COVID-19 vaccines, seeking damages and injunctions. These are ongoing claims, not a court decision, but they preserve potential legal and financial uncertainty. Arbutus litigation update

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Scotiabank increased their price target on shares of Pfizer from $33.00 to $35.00 and gave the company a “sector outperform” rating in a research report on Wednesday, November 4th. DZ Bank cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, November 6th. JPMorgan Chase & Co. lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Finally, Argus set a $40.00 target price on shares of Pfizer in a research report on Wednesday, November 4th. Six equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $30.39.

Get Our Latest Stock Analysis on Pfizer

Pfizer Trading Up 0.3%

Shares of NYSE:PFE opened at $29.32 on Wednesday. The business’s 50-day moving average is $28.79 and its 200 day moving average is $26.94. Pfizer Inc. has a 1 year low of $23.62 and a 1 year high of $31.44. The firm has a market capitalization of $167.13 billion, a P/E ratio of 9.58, a P/E/G ratio of 1.92 and a beta of 0.31. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.42 and a quick ratio of 1.10.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. The company had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. The firm’s revenue was down .4% compared to the same quarter last year. During the same period last year, the business posted $0.87 earnings per share. On average, research analysts predict that Pfizer Inc. will post 3.04 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 5.9%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is presently 245.71%.

About Pfizer

(Free Report)

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.

Featured Articles